The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada

Social Science and Medicine

Volumn 65, Issue 12, 2007, Pages 2553-2565

  Sarma, Sisira ^a   Basu, Kisalaya ^a   Gupta, Anil ^a  

^a Applied Research and Analysis Directorate   (Canada)

Author keywords

Canada; Drug utilization; Insurance; Latent class model; Non psychotropic drug; Psychotropic drug

Indexed keywords

PSYCHOTROPIC AGENT;

DRUG; HEALTH INSURANCE; HEALTH STATUS; MENTAL HEALTH; PUBLIC HEALTH; STOCHASTICITY;

ARTICLE; CANADA; DEMOGRAPHY; DRUG USE; DRUG UTILIZATION; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HEALTH STATUS; HEALTH SURVEY; HUMAN; INSURANCE; MENTAL HEALTH; POLICY; PRESCRIPTION; SELF REPORT; STOCHASTIC MODEL;

ADOLESCENT; ADULT; AGED; CANADA; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; PRESCRIPTIONS, DRUG; PSYCHOTROPIC DRUGS; SOCIOECONOMIC FACTORS; STOCHASTIC PROCESSES; UTILIZATION REVIEW;

CANADA; NORTH AMERICA;

EID: 36348949647     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2007.07.015     Document Type: Article

References (35)

1. Adams A.S., Soumerai B., and Ros-Degnan D. The case for Medicare drug benefit coverage: a critical review of the empirical evidence. Annual Review of Public Health 22 (2001) 49-61
2. Beck C.A., Williams J.V.A., Wang J.L., Kassam A., El-Guebaly N., Currie S.R., et al. Canadian Journal of Psychiatry 50 (2005) 605-613
3. Cameron, A.C., & Trivedi, P.K. (1998). Regression analysis of count data. In Econometric society monograph (Vol. 30). New York: Cambridge University Press.
4. Canadian Institute for Health Information. (2006). Drug expenditure in Canada: 1985 -2005. Ottawa.
5. Dev P., and Trivedi P.K. The demand for medical care by the elderly: a finite mixture approach. Journal of Applied Econometrics 12 (1997) 313-336
6. Dev P., and Trivedi P.K. The structure of demand for health care: latent class versus two-part models. Journal of Health Economics 21 (2002) 601-625
7. Dewa C.S., Hoch C.S., and Steele L. Prescription drug benefit and Canada's uninsured. International Journal of Law and Psychiatry 28 (2005) 496-513
8. Goldman D.P., Joyce G.F., Escarce J.J., Pace J.E., Solomon M.D., Laouri M., et al. Pharmacy benefits and the use of drugs by the chronically ill. Journal of the American Medical Association 291 19 (2004) 2344-2350
9. Grootendorst P., O'Brien B., and Anderson G.M. On becoming 65 in Ontario: Effects of drug plan eligibility on use of prescription medicines. Medical Care 35 (1997) 386-398
10. Hillman A.L., Pauly M.V., Escarce J.J., Ripley K., Gaynor M., Clouse J., et al. Health Affairs 18 2 (1999) 189-200
11. Hsu J., Price M., Huang J., Brand R., Fung V., Hui R., et al. Unintended consequences of caps on Medicare drug benefits. New England Journal of Medicine 354 22 (2006) 2349-2359
12. Huskamp H.A., Deverka P.A., Epstein A.M., Epstein R.S., McGuigan K.A., and Frank R.G. The effect of incentive-based formularies on prescription-drug utilization and spending. New England Journal of Medicine 349 23 (2003) 2224-2232
13. Jacobzone, S. (2000). Pharmaceutical policies in OECD countries: reconciling social and industrial goals. OECD Labour Market and Social Policy-Occasional Paper Number 40.
14. Johnson R.E., Goodman M.J., Hornbook M.C., and Eldredge M.B. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Medical Care 35 11 (1997) 1119-1131
15. Kapur V., and Basu K. Drug coverage in Canada: Who is at risk?. Health Policy 71 (2005) 181-193
16. Keeler E.B., and Rolph J.E. How cost sharing reduced medical spending of participants in the health insurance experiment. Journal of American Medical Association 249 16 (1983) 220-227
17. Kirby, M. (2002). Standing senate committee on social affairs, science and technology, The health of Canadians-The federal role. Final Report on the state of the health care system in Canada. Volume six: Recommendations for Reform. Ottawa.
18. Leibowitz A., Manning W.G., and Newhouse J.P. The demand for prescription drugs as a function of cost-sharing. Social Science & Medicine 21 (1985) 1063-1069
19. Lexchin J., and Grootendorst P. Effects of prescription drug use fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. International Journal of Health Services 34 1 (2004) 101-122
20. Lundberg L., Johannesson M., Isacson D.G., and Borgquist L. Effects of use charges on the use of prescription medicines in different socio-economic groups. Health Policy 44 2 (1998) 123-134
21. Martin B.C., and McMillan J.A. The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy and out-of-pocket expenditures. Medical Care 34 7 (1996) 686-701
22. Morgan S., McMahon M., Mooney D., and Raymond C. The Canadian Rx atlas (2005), Centre for Health Services and Policy Research, University of British Columbia, Vancouver
23. Motheral B.R., Henderson R., and Cox E.R. Plan-sponsor savings and member experience with point-of-service prescription step therapy. American Journal of Managed Care 10 7 (2004) 457-464
24. O'Brien B. The effect of patient charges on the utilization of prescription medicines. Journal of Health Economics 8 (1989) 109-132
25. Pauly M.V. The economics of moral hazard: Comment. American Economic Review 58 4 (1968) 531-537
26. Piette J.D., Heisler M., and Wagner T.H. Cost-related medication underuse among chronically ill adults: The treatments people forgo, how often, and who is at risk. American Journal of Public Health 94 10 (2004) 1782-1787
27. Romanow R. Building on values: The future of health care in Canada (2002), Commission on the Future of Health Care in Canada, Saskatoon
28. Rosen A.B., Hamel M.B., Weinstein M.C., Cutler D.M., Fendrick A.M., and Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Annals of Internal Medicine 143 2 (2005) 89-99
29. Sarma S., and Simpson W. A microeconometric analysis of Canadian health care utilization. Health Economics 15 3 (2006) 219-239
30. Soumerai S.B., Avorn J., Ross-Degnan D., and Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost and equity. New England Journal of Medicine 317 (1987) 550-556
31. Soumerai S.B., McLaughlin T.J., Ross-Degnan D., Casteris C.S., and Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331 (1994) 650-655
32. Statistics Canada. (2002). Canadian community health survey, Cycle 1.2 interviewer training guide. Ottawa: Statistics Canada.
33. Tamblyn R., Laprise R., Hanley J.A., Abrahamowicz M., Scott S., Mayo N., et al. Adverse events associated with prescription drugs cost-sharing among poor and elderly persons. Journal of American Medical Association 285 (2001) 421-429
34. World Health Organization. Dollars, DALYs and decisions: Economic aspects of the mental health system (2006), World Health Organization, Geneva
35. Zweifel P., and Manning W.G. Moral hazard and consumer incentives in health care. In: Culyer A.J., and Newhouse J.P. (Eds). Handbook of health economics Vol. 1A (2000), Elsevier, Amsterdam 409-459